Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018
MINNEAPOLIS , May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery and producer of the FDA -approved STREAMWAY® System for automated,
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on May 15, 2018
MINNEAPOLIS , May 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML
Toggle Summary Precision Therapeutics, Inc. Signs Letter of Intent to Purchase Remainder of Helomics Corporation Shares
MINNEAPOLIS , April 23, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has signed an LOI to acquire the remainder of the
View HTML
Toggle Summary Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary
Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D cell culturing from 48 Hour Discovery, SyntArray and CellBridge MINNEAPOLIS , April 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc.
View HTML
Toggle Summary CORRECTING and REPLACING - Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
In a release issued under the same headline earlier today by Precision Therapeautics (NASDAQ:AIPT), please note that the forward-looking statements paragraph was missing. The corrected release follows: MINNEAPOLIS , April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc.
View HTML
Toggle Summary Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
MINNEAPOLIS , April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, today released highlights from its business update
View HTML
Toggle Summary Precision Therapeutics Reports Fiscal Year 2017 Financial Results
Company reports strengthening STREAMWAY® System sales and new strategic focus on the emerging precision medicine market MINNEAPOLIS , April 02, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying
View HTML
Toggle Summary Precision Therapeutics Announces Record STREAMWAY® System Sales in the First Three Months of 2018
Sixteen STREAMWAY Systems sold in Q1 2018, compared with five units sold in Q4 2017 and three sold in Q1 2016 MINNEAPOLIS , March 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), today provided a sales update from its Skyline Medical division,
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018
MINNEAPOLIS , March 26, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated
MINNEAPOLIS , March 21, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with CellBridge Incorporated (“CellBridge”)
View HTML